



Basic information	
<b>2020/2153(DEC)</b> DEC - Discharge procedure	Procedure completed
2019 discharge: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)	
<b>Subject</b> 8.70.03.09 2019 discharge	

Key players			
European Parliament	Committee responsible		Rapporteur
	<div>CONT</div> Budgetary Control		CZARNECKI Ryszard (ECR)
			Shadow rapporteur ZDECHOVSKÝ Tomáš (EPP) RÓNAI Sándor (S&D) STRUGARIU Ramona (Renew) EICKHOUT Bas (Greens /EFA) OMARJEE Younous (GUE /NGL)
	Committee for opinion		Rapporteur for opinion
	<div>ENVI</div> Environment, Public Health and Food Safety		The committee decided not to give an opinion.
	<div>LIBE</div> Civil Liberties, Justice and Home Affairs		CHINNICI Caterina (S&D)
European Commission	Commission DG		Commissioner
	Budget		HAHN Johannes

Key events			
Date	Event	Reference	Summary
		COM(2020)0288	

29/06/2020	Non-legislative basic document published		
15/09/2020	Committee referral announced in Parliament		
22/03/2021	Vote in committee		
30/03/2021	Committee report tabled for plenary	<a href="#">A9-0087/2021</a>	
27/04/2021	Debate in Parliament		
28/04/2021	Decision by Parliament	<a href="#">T9-0177/2021</a>	<a href="#">Summary</a>
24/09/2021	Final act published in Official Journal		

Technical information	
Procedure reference	2020/2153(DEC)
Procedure type	DEC - Discharge procedure
Other legal basis	Rules of Procedure EP 165
Stage reached in procedure	Procedure completed
Committee dossier	CONT/9/03863

Documentation gateway


European Parliament

Document type	Committee	Reference	Date	Summary
Committee draft report		<a href="#">PE657.224</a>	12/01/2021	
Committee opinion	<div>LIBE</div>	<a href="#">PE661.917</a>	25/02/2021	
Amendments tabled in committee		<a href="#">PE680.788</a>	04/03/2021	
Committee report tabled for plenary, single reading		<a href="#">A9-0087/2021</a>	30/03/2021	
Text adopted by Parliament, single reading		<a href="#">T9-0177/2021</a>	28/04/2021	<a href="#">Summary</a>

Council of the EU

Document type	Reference	Date	Summary
Supplementary non-legislative basic document	05793/2021	05/02/2021	

European Commission

Document type	Reference	Date	Summary
Non-legislative basic document	<a href="#">COM(2020)0288</a> 	29/06/2020	

Final act

# 2019 discharge: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

2020/2153(DEC) - 28/04/2021 - Text adopted by Parliament, single reading

The European Parliament decided by 636 votes to 53, with 9 abstentions, to give discharge to the Director of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) for the financial year 2019 and to approve the closure of the accounts for that year.

Noting that the Court of Auditors stated that it had obtained reasonable assurance that the Centre's annual accounts for the financial year 2019 were reliable and that the underlying transactions were legal and regular, Parliament adopted, by 628 votes to 58 with 5 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations contained in the [resolution](#) on the performance, financial management and control of EU agencies.

## ***Centre's financial statements***

The EMCDDA's final budget for the financial year 2019 was EUR 18 178 352.57, which is an increase of 12.39% compared to 2018. The increase in the budget is mainly due to the launch of the new Instrument for Pre-Accession Assistance 7 (IPA 7).

## ***Budgetary and financial management***

Parliament welcomed the budget monitoring efforts made during the 2019 financial year, which resulted in a budget implementation rate of 100%, identical to that recorded in 2018. The implementation rate of payment appropriations was 98.29%, an increase of 0.28% compared to the previous year.

## ***Other observations***

Members also made a series of observations concerning performance, staff, procurement, conflict of interest management and internal controls.

In particular, they noted that:

- the 2019 work programme is largely implemented and the Centre has introduced a new performance measurement model in 2019;
- the Centre plays an important role in providing policy makers and practitioners with a range of analysis and information on drugs and drug addiction and trends, with a view to effectively combating drug abuse and trafficking;
- the Centre partially met its objective in terms of training days per staff member, in terms of public service costs and in terms of its contribution to 14 major scientific and practice drug events;
- on 31 December 2019, 94.74% of the establishment plan was executed with 9 officials and 63 temporary agents appointed out of the 10 officials and 66 temporary agents authorised under the Union's budget;
- the Centre recorded a close gender balance within the Management Board in 2019 (16 men and 14 women) but the geographical balance of staff needs to be improved;
- the issue of dependence on external recruitment needs to be addressed and applicable labour law respected;
- in 85 out of 92 procedures, representing 60% of the total value of the contracts, the Centre attributed direct contracts in procedures with single tenders. Members recommended the use of procedures involving multi candidates, even for low-value contracts;
- the Centre has taken steps to ensure transparency, prevent and manage conflicts of interest and protect whistleblowers; Members called for the creation of a common ethical framework for all EU institutions and agencies;
- the final version of the repository for the new internal control framework was approved by the Centre's Director in March 2019 but the anti-fraud strategy should be updated.